

CLAIM AMENDMENTS

1. (Currently Amended) A method of chemosensitizing tumor tissue <sup>in vivo</sup> comprising administration of a chemotherapeutic agent and a composition comprising cationic liposomes, which consist of cationic lipid, phosphatidylcholine and cholesterol, and having encapsulated therein ~~as least one~~ <sup>AN</sup> oligonucleotide, wherein said oligonucleotide ~~targets raf~~ <sup>SEQUENCE</sup> comprises the formula 5'-GTGCTCCATTGATGC-3' (SEQ ID NO:1) and wherein the chemotherapeutic agent is selected from a group consisting of mitoxantrone, cisplatin, epirubicin, and ~~Gemzar~~ <sup>GEMZAR</sup>.
2. (Currently Amended) The method of claim 1, wherein the oligonucleotide <sup>comprises up</sup> ~~ranges in~~ size ~~from 10~~ <sup>5' AND 3' TERMINAL</sup> to 40 nucleotides and is phosphorothioated at only the end-nucleotides.
3. (Previously Presented) The method of claim 1, wherein the oligonucleotide <sup>up</sup> ~~comprises~~ 10 to 40 nucleotides and all of its bases are phosphorothioated.
4. (Previously Presented) The method of claim 1, wherein the oligonucleotide <sup>up</sup> ~~comprises~~ 10 to 40 nucleotides, wherein <sup>The oligonucleotide is</sup> ~~all of its bases are modified in~~ a <sup>OLIGONUCLEOTIDE</sup> ~~chimeric~~ form.
5. (Previously Presented) The method of claim 1, wherein the oligonucleotide is - administered intravenously.
6. (Previously Presented) The method of claim 1, wherein the oligonucleotide is administered directly to the target tissue.
7. (Previously Presented) The method of claim 1, wherein the oligonucleotide is administered into the arterial supply to the target tissue.
8. (Previously Presented) The method of claim 1, wherein said oligonucleotide is an antisense DNA.
9. (Canceled)
10. (Canceled)
11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Previously Presented) The method of claim 1, wherein the tumor tissue is caused by cancer.

18. (Previously Presented) The method of claim 1, wherein the oligonucleotide is administered before or after the chemotherapeutic agent.

19. (Canceled)

20. (Canceled)

21. (Currently Amended) The method of claim 1, wherein the oligonucleotide is administered before or after a combination of radiation and the a-chemotherapeutic agent.

22. (Canceled)

23. (Previously Presented) The method of claim 17, wherein the cancer is selected from a group <sup>CONSISTING</sup> ~~consisted~~ of leukemia, lymphoma, myeloma, carcinoma <sup>AND</sup> ~~or~~ sarcoma. <sup>the</sup>